- Home
- THW vs MREO Comparison
THW vs MREO Comparison
Compare THW & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THW
- MREO
- Stock Information
- Founded
- THW 2015
- MREO 2015
- Country
- THW United States
- MREO United Kingdom
- Employees
- THW N/A
- MREO N/A
- Industry
- THW Finance Companies
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- THW Finance
- MREO Health Care
- Exchange
- THW Nasdaq
- MREO Nasdaq
- Market Cap
- THW 391.1M
- MREO 424.5M
- IPO Year
- THW N/A
- MREO N/A
- Fundamental
- Price
- THW $10.54
- MREO $2.74
- Analyst Decision
- THW
- MREO Strong Buy
- Analyst Count
- THW 0
- MREO 7
- Target Price
- THW N/A
- MREO $7.71
- AVG Volume (30 Days)
- THW 149.9K
- MREO 1.1M
- Earning Date
- THW 01-01-0001
- MREO 05-13-2025
- Dividend Yield
- THW 10.76%
- MREO N/A
- EPS Growth
- THW N/A
- MREO N/A
- EPS
- THW N/A
- MREO N/A
- Revenue
- THW N/A
- MREO N/A
- Revenue This Year
- THW N/A
- MREO N/A
- Revenue Next Year
- THW N/A
- MREO $54.07
- P/E Ratio
- THW N/A
- MREO N/A
- Revenue Growth
- THW N/A
- MREO N/A
- 52 Week Low
- THW $9.76
- MREO $1.58
- 52 Week High
- THW $14.89
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- THW 52.34
- MREO 63.12
- Support Level
- THW $10.10
- MREO $2.44
- Resistance Level
- THW $10.51
- MREO $2.71
- Average True Range (ATR)
- THW 0.15
- MREO 0.16
- MACD
- THW 0.04
- MREO 0.05
- Stochastic Oscillator
- THW 73.33
- MREO 96.18
About THW abrdn World Healthcare Fund Shares of Beneficial Interest
Tekla World Healthcare Fund is a diversified closed-end management investment company. Its investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies engaged in the healthcare industry. The company's investment portfolio comprises investments in different sub-sectors such as pharmaceuticals and biotechnology, healthcare providers and services, real estate investment trusts, medical devices and diagnostics, and other areas. It also male into REIT Real Estate.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).